Companies making headlines after the bell Thursday:
Dow has worst day in six months amid concerns from Ukraine, Portugal and Argentina. U.S. economic data and earnings weighed too.
The golden state's drought has gotten worse, and one analyst said it's possible that migrating people out of California may be an option.
Ron Insana says he expects a near-term correction. He's out of stocks and has taken short positions.
Warren Buffett called into CNBC to surprise 17-year-old Tre Grinner, a Hodgkin's Lymphoma patient who wants to be an investment banker.
The stock market could suffer further declines should one of three major things happen Thursday, veteran trader Art Cashin says.
A demoted Chicago worker shot and critically wounded his company's CEO before fatally shooting himself Thursday.
The iPhone 6 launch would be part of an "incredibly busy" month of October, according to MacRumors.
It could be the world's most expensive fake. A 1962 Ferrari GTO is being offered for $63 million on a German website.
Legalizing pot is going to exacerbate income inequality in America, says Jake Novak. Here's why.
Stocks are sharply lower, with European stocks trading ugly right from the start.
Some of Wednesday's midday movers:
Argentine banks are expected to offer to buy debt owned by holdout investors suing country in a bid to avert default, a banking executive said.
The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.
Real estate Web sites Zillow and Trulia have crafted a clever deal to send their high-flying share prices to even greater heights.
Corporate tax reform still won't stop companies from seeking inversion deals, a co-sponsor of anti-inversion legislation said.
Japanese video game maker Nintendo posted a worse-than-expected operating loss in the second quarter as it struggles with shrinking sales.
Total stopped buying shares in Russia's Novatek the day of the downing of a Malaysia Airlines flight over Ukraine.
Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
Shares rallied into earnings and then declined immediately thereafter. Cramer says there was no reason.